Insider Selling: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Sells 1,194 Shares of Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze sold 1,194 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $37.92, for a total value of $45,276.48. Following the completion of the sale, the executive vice president now owns 33,713 shares of the company’s stock, valued at approximately $1,278,396.96. This represents a 3.42 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Eric Swayze also recently made the following trade(s):

• On Wednesday, October 16th, Eric Swayze sold 53 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $38.31, for a total value of $2,030.43.

Ionis Pharmaceuticals Trading Down 7.8 %

Shares of IONS opened at $34.34 on Friday. The firm has a market cap of $5.42 billion, a P/E ratio of -14.07 and a beta of 0.39. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $34.24 and a fifty-two week high of $54.44. The company has a debt-to-equity ratio of 1.86, a quick ratio of 8.82 and a current ratio of 8.91. The business has a 50-day moving average of $39.62 and a 200 day moving average of $42.75.

Institutional Trading of Ionis Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Mather Group LLC. grew its stake in Ionis Pharmaceuticals by 35.8% in the 2nd quarter. Mather Group LLC. now owns 911 shares of the company’s stock valued at $39,000 after buying an additional 240 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of Ionis Pharmaceuticals by 3.5% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 7,624 shares of the company’s stock worth $363,000 after acquiring an additional 261 shares during the period. Nicollet Investment Management Inc. grew its position in shares of Ionis Pharmaceuticals by 1.5% in the third quarter. Nicollet Investment Management Inc. now owns 20,402 shares of the company’s stock valued at $817,000 after purchasing an additional 294 shares in the last quarter. Amalgamated Bank raised its stake in shares of Ionis Pharmaceuticals by 3.1% during the 3rd quarter. Amalgamated Bank now owns 9,957 shares of the company’s stock valued at $399,000 after purchasing an additional 300 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in Ionis Pharmaceuticals by 83.9% during the 3rd quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock worth $27,000 after purchasing an additional 303 shares in the last quarter. Institutional investors own 93.86% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. TD Cowen increased their target price on Ionis Pharmaceuticals from $54.00 to $59.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Bank of America boosted their price objective on Ionis Pharmaceuticals from $67.00 to $68.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Needham & Company LLC restated a “buy” rating and issued a $60.00 target price on shares of Ionis Pharmaceuticals in a report on Thursday, November 7th. Leerink Partners upgraded Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $53.00 to $62.00 in a report on Wednesday, July 24th. Finally, Wells Fargo & Company dropped their price objective on Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating on the stock in a research note on Thursday, November 7th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Ionis Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $60.65.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.